Group items matching

in title, tags, annotations or url

The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drug's impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of CUDs or their consequences such as withdrawal, craving, or cannabis use relapse. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of CUDs. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

The Science of Learning program supports potentially transformative basic research to advance the science of learning. The goals of the SL Program are to develop basic theoretical insights and fundamental knowledge about learning principles, processes and constraints. Projects that are integrative and/or interdisciplinary may be especially valuable in moving basic understanding of learning forward but research with a single discipline or methodology is also appropriate if it addresses basic scientific questions in learning. The possibility of developing connections between proposed research and specific scientific, technological, educational, and workforce challenges will be considered as valuable broader impacts, but are not necessarily central to the intellectual merit of proposed research. The program will support research addressing learning in a wide range of domains at one or more levels of analysis including: molecular/cellular mechanisms; brain systems; cognitive affective, and behavioral processes; and social/cultural influences. The program supports a variety of methods including: experiments, field studies, surveys, secondary-data analyses, and modeling.

The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. Also listed under R21.

Through the program, two grants of $25,000 will be awarded to graduate student researchers interested in exploring the gut microbiome, probiotics, and yogurt and how they help support and maintain human health and wellness. Topics may include the role that probiotics or yogurt play on brain function, growth and development, digestive health, weight management or heart health; and factors such as foods or nutrients that influence the gut microbiome. The grant is not designed for the investigation of disease treatment or clinical management and should focus on health and wellness, long-term health and longevity, growth and development, and/or performance.

The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Specifically, this RFP focuses on: - developing novel PET ligands for clinical use - supporting novel CSF biomarkers - validating established MRI approaches in larger cohorts Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include: - Neuronal loss - Vascular injury and blood-brain barrier integrity - Mitochondria and metabolic function - Protein misfolding/proteostasis - Oxidative stress - White matter changes - Other novel targets supported by compelling biological rationale and connection to disease The ADDF has limited interest in CSF measures of amyloid and tau.

To support generation of single cell RNA-sequencing data sets for at least one brain region relevant to persistent HIV infection and opioid, cocaine and/or methamphetamine use disorder

The ODC is offering 38 research opportunities focusing on 29 different rare diseases. This program provides a one-year grant to support research related to a rare disease represented in the 2020 Million Dollar Bike Ride. Number of awards and dollar amounts vary per disease based on fundraising totals by each disease team. Diseases included: * Adult Polyglucosan Body Disease (APBD) * Ataxia-Telangiectasia (A-T) * BPAN- A Neurodegeneration with Brain Iron Accumulation Disorder * CADASIL * Castleman Disease * Choroideremia * Congenital Hyperinsulinism (CHI) * Congenital Muscular Dystrophy (CMD) * Charcot Maire Tooth (CMT) * Cohen Syndrome (COH) * Nonsense Mutations in Cystic Fibrosis * Dyskeratosis Congenita & Telomere Biology Disorder * Fibrous Dysplasia/McCune Albright Syndrome * Fibrodysplasia Ossificans Progressiva (FOP) * Generalized Lymphatic Anomaly (GLA; a.k.a. lymphangiomatosis) and * Gorham-Stout Disease (GSD) * Glut1 Deficiency Sundrome * Inclusion Body Myositis (IBM) * Lymphangioleiomyomatosis (LAM) * Mucopolysaccharidoses (MPS) * MPS Gene Spotlight: Mucopolysaccharidosis (MPS I) * Maple Syrup Urine Disease (MSUD) * Mitochondrial Complex 1 Deficiency Disorder - NUBPL * Neuroendocrine cell Hyperplasia of Infancy (NEHI) * Niemann Pick Type C (NPC) * Pitt Hopkins Syndrome (PTHS) * RASopathies * SETBP1 Disorder * Snyder-Robinson Syndrome (SRS) * STXBP1 Encephalopathy * TBCK Syndrome

The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena.  Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics. The projects under this FOA will develop novel methods, theories, and approaches through a CN team framework, bringing together highly synergistic inter/transdisciplinary teams from neuroscience and "orthogonal" fields (e.g., data/computational science, physics, engineering, mathematics, and environmental sciences). Successful teams will combine, expand upon, or develop conceptual frameworks and theoretical approaches, and build explanatory computational models that connect contiguous levels of analysis. Such frameworks, theories, and computational explanatory models should be validated through experimental approaches to elucidate biological underpinnings of complex behavioral (including cognitive and affective) outcomes in psychopathology. Additionally, a goal of this program is to advance research in CN by creating a shared community framework of resources which may be used by the broader research community to further research, as such, successful team will have robust plan for sharing data and other resources.

The Society for the Study of Psychiatry and Culture announces its annual call for papers for the Charles Hughes Fellowship and the John Spiegel Fellowship in Cultural Psychiatry. The Charles Hughes Fellowship is an annual award presented to a graduate student who has an interest in and commitment to cultural psychiatry and mental health. The John Spiegel Fellowship is an annual award presented to a resident in clinical training who is dedicated to improving clinical care through culturally-informed practice.

We fund projects at each stage of the drug development pipeline to ensure promising leads are advanced as quickly as possible. Our pre-clinical screening program breaks down barriers to entry, our academic grants focus on novel therapies, and our industry investments bring the most promising treatments to patients quickly.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in the use of ABCD data. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experience involving cooperative and competitive use of ABCD datas